What is yellow fever

Overview

Yellow fever is one of history's most feared infectious diseases — a viral hemorrhagic illness that shaped the course of colonial history, drove devastating epidemics across three continents for more than three centuries, and ultimately spurred some of the most consequential advances in the history of vaccinology. The disease is caused by the yellow fever virus (YFV), a single-stranded, positive-sense RNA virus belonging to the genus Flavivirus within the family Flaviviridae — the same taxonomic family that includes the viruses responsible for dengue fever, Zika disease, West Nile encephalitis, and Japanese encephalitis. Yellow fever is transmitted to humans primarily through the bite of infected female Aedes aegypti mosquitoes, though several other Aedes and Haemagogus species can also serve as competent vectors under certain ecological conditions.

The disease acquired its common name from one of its most visually striking manifestations: jaundice, the yellowing of the skin and whites of the eyes caused by the accumulation of bilirubin when the liver sustains severe inflammatory damage. In the most severe cases, yellow fever also produces systemic hemorrhagic bleeding — including the notorious black vomit, the vomiting of digested blood from gastrointestinal hemorrhage that was historically considered a near-certain death sentence and became one of the disease's most feared hallmarks. The earliest reliable historical descriptions of what is believed to be yellow fever date to the 17th century in the Caribbean. Major epidemics subsequently struck the eastern seaboard of the United States — including a devastating 1793 outbreak in Philadelphia that killed approximately 5,000 people, representing roughly 10% of the city's total population at the time — as well as West Africa, the Caribbean islands, and Latin America. For more than two centuries, yellow fever was among the deadliest and most disruptive epidemic diseases known to medicine.

Today, yellow fever remains an active endemic disease affecting tropical and subtropical regions of Africa and South America. The World Health Organization (WHO) estimates approximately 200,000 infections and 30,000 deaths per year globally, with roughly 90% of cases occurring in sub-Saharan Africa. Despite the availability of a safe, inexpensive, and highly effective vaccine for nearly 90 years, yellow fever continues to cause periodic outbreaks due to incomplete vaccination coverage in endemic regions, ongoing urbanization that expands mosquito habitats, and climate factors influencing the geographic range of Aedes aegypti mosquito populations.

Transmission, Symptoms, and Disease Progression

Yellow fever is transmitted in three distinct epidemiological cycles reflecting different environments and human exposure patterns. In the sylvatic (jungle) cycle, the virus circulates among non-human primates — primarily monkeys — and forest-dwelling mosquitoes of the Haemagogus and Sabethes genera in the Americas, or Aedes africanus in Africa. Humans who enter forest ecosystems for logging, agriculture, road construction, or ecotourism may be incidentally infected when bitten by these forest mosquitoes. The intermediate (savannah) cycle, primarily observed in humid savannah regions of Africa, involves semi-domestic mosquito species infecting both monkeys and humans in villages near forest margins. The urban cycle — epidemiologically the most dangerous — occurs when Aedes aegypti mosquitoes in densely populated cities transmit the virus from person to person, enabling rapid spread through large populations with little or no prior immunity. Most of history's catastrophic yellow fever epidemics were driven by urban transmission cycles occurring in cities with dense, non-immune human populations and high densities of domestic Aedes aegypti mosquitoes.

Following a mosquito bite, the incubation period is typically 3 to 6 days. The clinical illness then progresses through clearly defined stages that clinicians have recognized for centuries:

• Acute phase (days 1–3): Abrupt onset of fever, severe headache, myalgia (particularly in the back and knees), nausea, vomiting, and profound fatigue. A characteristic clinical finding called Faget's sign — a paradoxical slowing of the heart rate (bradycardia) despite the presence of high fever — may be observed during this phase and helps distinguish yellow fever from other acute febrile illnesses in endemic settings.
• Period of remission (12–48 hours): Symptoms subside, temperature normalizes, and most patients begin to feel markedly better. Approximately 85% of infected individuals recover fully during or after this phase without any further progression of illness.
• Toxic phase (approximately 15% of patients): Within 24 hours of apparent recovery, roughly 15% of patients experience a dramatic clinical deterioration. High fever returns, accompanied by severe jaundice from extensive hepatocellular damage, acute kidney injury progressing toward failure, hemorrhagic manifestations including bleeding from the gums, nose, and gastrointestinal tract, and the signature black vomit — hematemesis containing digested blood — that made yellow fever so recognizable and so feared historically. The case fatality rate in the toxic phase ranges from 20% to 50%, and death typically occurs between 7 and 10 days after symptom onset in patients who do not recover.

There is currently no specific antiviral medication approved or proven effective for treating yellow fever once infection has occurred. Clinical management is entirely supportive: intravenous fluid administration to correct dehydration and maintain circulation, antipyretics to manage fever with avoidance of aspirin and nonsteroidal anti-inflammatory drugs due to the risk of worsening hemorrhagic bleeding, close monitoring and support of liver and kidney function, prompt treatment of secondary bacterial infections with antibiotics, and intensive care unit support for patients in the toxic phase who require mechanical ventilation or renal replacement therapy. Patients who survive the toxic phase generally recover completely over a period of several weeks and develop permanent, lifelong natural immunity to reinfection by the yellow fever virus.

Common Misconceptions About Yellow Fever

Misconception 1: Yellow fever is only a risk in Africa. While sub-Saharan Africa accounts for approximately 90% of global yellow fever cases each year, the disease is also actively endemic throughout large portions of tropical South America. High-risk areas include the Amazon basin and adjacent regions of Brazil, Peru, Colombia, Bolivia, Ecuador, and Venezuela. Brazil experienced a particularly severe and alarming outbreak from 2016 to 2019, primarily affecting the southeastern states of Minas Gerais, Sao Paulo, and Rio de Janeiro — regions that had not seen significant yellow fever transmission for several decades and consequently had relatively low vaccination coverage in their resident populations. That outbreak resulted in over 2,000 confirmed human cases and more than 670 deaths, and prompted emergency vaccination campaigns that administered millions of fractional vaccine doses to rapidly expand population immunity. The outbreak underscored that yellow fever is not solely an African health concern and that urban-adjacent outbreaks remain a genuine modern threat in South America.

Misconception 2: The yellow fever vaccine requires a booster dose every 10 years. For several decades, international travel health regulations required travelers to show proof of yellow fever vaccination received within the previous 10 years. In April 2013, the WHO's Strategic Advisory Group of Experts on Immunization (SAGE) reviewed the cumulative scientific evidence on vaccine-induced immunity duration and concluded that a single dose of the yellow fever vaccine provides lifelong protective immunity for the vast majority of recipients, making booster doses unnecessary for continued protection. The WHO formally updated its position statement, and the International Health Regulations were subsequently revised in 2016 to reflect this change. As a result, International Certificates of Vaccination or Prophylaxis (ICVP) for yellow fever issued after that revision are now valid for the life of the document holder following a single dose, rather than the previous 10-year validity period — though a small number of specific countries and certain high-risk populations may retain different requirements.

Misconception 3: Yellow fever has been eradicated or will soon be eliminated as a disease. Yellow fever has not been eradicated and is not currently on a realistic near-term eradication trajectory. Unlike smallpox, which was declared globally eradicated in 1980 through an intensive worldwide vaccination campaign, yellow fever cannot be eradicated because the virus maintains a permanent, self-sustaining animal reservoir in wild non-human primate populations living in jungle ecosystems across Africa and South America. Vaccination programs protect human populations effectively but cannot eliminate the virus from its natural zoonotic reservoir. The WHO's Eliminate Yellow Fever Epidemics (EYE) strategy, launched in 2017 as a collaboration between WHO, UNICEF, and Gavi, the Vaccine Alliance, aims to protect more than 1 billion people in 40 high-risk countries by 2026 through expanded vaccination, enhanced surveillance, and improved outbreak response capacity — but the program's stated goal is epidemic elimination in human populations, not viral eradication from nature, which is not considered biologically feasible.

Prevention, Vaccination, and Travel Health Guidance

The yellow fever vaccine is widely regarded as one of the most effective vaccines ever developed. The live attenuated 17D strain, developed by South African virologist Max Theiler working at the Rockefeller Institute in New York in 1937, produces protective immunity in more than 99% of vaccine recipients within 30 days of a single subcutaneous injection. Theiler was awarded the Nobel Prize in Physiology or Medicine in 1951 for this achievement — one of the very few Nobel Prizes ever awarded specifically for the development of a vaccine. The 17D vaccine strain remains the basis of all yellow fever vaccines used worldwide today, nearly 90 years after its development. The vaccine is generally well tolerated, with most recipients experiencing only mild and transient side effects such as low-grade fever, mild headache, or injection site soreness lasting 5 to 10 days post-vaccination.

Certain populations require additional clinical consideration before receiving the yellow fever vaccine. Infants under 9 months of age should not receive the vaccine due to an elevated risk of vaccine-associated encephalitis. Individuals with severe immunosuppression — from advanced HIV infection with CD4 cell counts below 200 per microliter, active chemotherapy, high-dose systemic corticosteroids, or organ transplantation — may be unable to mount an adequate immune response and face increased risk of vaccine-associated adverse events. A rare but potentially fatal adverse event known as yellow fever vaccine-associated viscerotropic disease (YEL-AVD), in which the attenuated vaccine virus replicates systemically and causes multi-organ failure clinically similar to wild-type yellow fever, occurs at an estimated rate of approximately 0.3 to 0.4 cases per 100,000 vaccine doses administered, with a fatality rate of approximately 60% among those affected. The risk of YEL-AVD is substantially higher in first-time vaccine recipients over 60 years of age, making individualized risk-benefit assessment particularly important for older travelers considering vaccination before visiting endemic regions.

For international travelers, yellow fever vaccination serves both a personal health protective function and, in many cases, a legal regulatory function at national borders. Under the International Health Regulations, approximately 40 countries require proof of yellow fever vaccination for entry, particularly for travelers arriving from or transiting through countries with endemic yellow fever transmission in Africa or South America. The vaccination must be administered at an authorized yellow fever vaccination center — in the United States, these are designated by state health departments — and the official documentation of vaccination is an International Certificate of Vaccination or Prophylaxis (ICVP), commonly known as the yellow card. In addition to vaccination, travelers to endemic regions should apply insect repellent containing at least 30% DEET to exposed skin, wear long-sleeved shirts and long trousers during dawn and dusk when Aedes aegypti mosquitoes are most active, treat clothing and gear with permethrin, and sleep under insecticide-treated bed nets when accommodations are not fully screened or air-conditioned, as these complementary measures provide meaningful additional protection beyond what vaccination alone can offer.